undamentalytics Newsletter
Sign in

Arcus Biosciences, Inc. cash flow statement

In fiscal 2025, Arcus Biosciences, Inc.'s operations generated −$482m of cash; it spent $2.0m on capital projects, leaving free cash flow of −$484m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−25−43−73111−256438−306−170−482−474
Depreciation and amortisation3443468101010
Stock-based pay04922556573766063
Capital spending642326624621
Free cash flow−31−47−75108−282432−330−176−484−475
Free cash flow after stock pay−31−51−8486−337367−403−252−544−538
Share buybacks—00———————
Shares issued—41434220025228429287

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: RCUS vs SPRYMESO vs RCUSRCUS vs XNCRAGEN vs RCUS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcus Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcus Biosciences, Inc.